Current concepts in the diagnosis and management of cytokine release syndrome

Blood - Tập 124 - Trang 188-195 - 2014
Daniel W. Lee1, Rebecca Gardner2, David L. Porter3, Chrystal U. Louis4, Nabil Ahmed4, Michael Jensen2, Stephan A. Grupp3,5, Crystal L. Mackall1
1Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD;
2Seattle Children's Hospital, Seattle, WA
3Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA
4Texas Children’s Hospital, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and
5Children’s Hospital of Philadelphia Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Tóm tắt

Abstract As immune-based therapies for cancer become potent, more effective, and more widely available, optimal management of their unique toxicities becomes increasingly important. Cytokine release syndrome (CRS) is a potentially life-threatening toxicity that has been observed following administration of natural and bispecific antibodies and, more recently, following adoptive T-cell therapies for cancer. CRS is associated with elevated circulating levels of several cytokines including interleukin (IL)-6 and interferon γ, and uncontrolled studies demonstrate that immunosuppression using tocilizumab, an anti-IL-6 receptor antibody, with or without corticosteroids, can reverse the syndrome. However, because early and aggressive immunosuppression could limit the efficacy of the immunotherapy, current approaches seek to limit administration of immunosuppressive therapy to patients at risk for life-threatening consequences of the syndrome. This report presents a novel system to grade the severity of CRS in individual patients and a treatment algorithm for management of CRS based on severity. The goal of our approach is to maximize the chance for therapeutic benefit from the immunotherapy while minimizing the risk for life threatening complications of CRS.

Tài liệu tham khảo

Kolb, 2008, Graft-versus-leukemia effects of transplantation and donor lymphocytes., Blood, 112, 4371, 10.1182/blood-2008-03-077974 Weiner, 2010, Rituximab: mechanism of action., Semin Hematol, 47, 115, 10.1053/j.seminhematol.2010.01.011 Clynes, 2000, Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets., Nat Med, 6, 443, 10.1038/74704 Kantoff, 2010, Sipuleucel-T immunotherapy for castration-resistant prostate cancer., N Engl J Med, 363, 411, 10.1056/NEJMoa1001294 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma., N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer., N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 Topp, 2011, Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival., J Clin Oncol, 29, 2493, 10.1200/JCO.2010.32.7270 Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia., N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134 Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia., N Engl J Med, 365, 725, 10.1056/NEJMoa1103849 Kochenderfer, 2012, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells., Blood, 119, 2709, 10.1182/blood-2011-10-384388 Pule, 2008, Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma., Nat Med, 14, 1264, 10.1038/nm.1882 Robbins, 2011, Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1., J Clin Oncol, 29, 917, 10.1200/JCO.2010.32.2537 Rosenberg, 2008, Adoptive cell transfer: a clinical path to effective cancer immunotherapy., Nat Rev Cancer, 8, 299, 10.1038/nrc2355 Brentjens Page, 2014, Immune modulation in cancer with antibodies., Annu Rev Med, 65, 185, 10.1146/annurev-med-092012-112807 Cameron Linette, 2013, Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma., Blood, 122, 863, 10.1182/blood-2013-03-490565 Morgan, 2013, Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy., J Immunother, 36, 133, 10.1097/CJI.0b013e3182829903 Wing, 1996, Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells., J Clin Invest, 98, 2819, 10.1172/JCI119110 Suntharalingam, 2006, Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412., N Engl J Med, 355, 1018, 10.1056/NEJMoa063842 Chatenoud, 1990, In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids., Transplantation, 49, 697, 10.1097/00007890-199004000-00009 Winkler, 1999, Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)., Blood, 94, 2217, 10.1182/blood.V94.7.2217.419k02_2217_2224 Teachey, 2013, Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy., Blood, 121, 5154, 10.1182/blood-2013-02-485623 Reagan, 2013, Cellular immunotherapy for refractory hematological malignancies., J Transl Med, 11, 150, 10.1186/1479-5876-11-150 Morgan, 2010, Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2., Mol Ther, 18, 843, 10.1038/mt.2010.24 Davila Brentjens, 2010, Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial., Mol Ther, 18, 666, 10.1038/mt.2010.31 Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia., Sci Transl Med, 3, 95ra73, 10.1126/scitranslmed.3002842 Nishimoto, 2006, Interleukin 6: from bench to bedside., Nat Clin Pract Rheumatol, 2, 619, 10.1038/ncprheum0338 Scheller, 2011, The pro- and anti-inflammatory properties of the cytokine interleukin-6., Biochim Biophys Acta, 1813, 878, 10.1016/j.bbamcr.2011.01.034 Romero-Bermejo, 2011, Sepsis-induced cardiomyopathy., Curr Cardiol Rev, 7, 163, 10.2174/157340311798220494 Singh, 2014, Meta-analysis of clinical correlates of acute mortality in takotsubo cardiomyopathy., Am J Cardiol, 113, 1420, 10.1016/j.amjcard.2014.01.419 Kashiwagi, 2014, Clinico-radiological spectrum of reversible splenial lesions in children., Brain Dev, 36, 330, 10.1016/j.braindev.2013.05.007 Spooren, 2011, Interleukin-6, a mental cytokine., Brain Res Brain Res Rev, 67, 157, 10.1016/j.brainresrev.2011.01.002 Weber, 1994, A phase I trial of intravenous interleukin-6 in patients with advanced cancer., J Immunother Emphasis Tumor Immunol, 15, 292, 10.1097/00002371-199405000-00008 Kometani, 2014, Marked elevation of interleukin-6 in mild encephalopathy with a reversible splenial lesion (MERS) associated with acute focal bacterial nephritis caused by Enterococcus faecalis., Brain Dev, 36, 551, 10.1016/j.braindev.2013.07.012 Billiau, 2005, Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages., Blood, 105, 1648, 10.1182/blood-2004-08-2997 Schultz, 1990, Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen., Semin Arthritis Rheum, 20, 129, 10.1016/0049-0172(90)90055-K Pepys, 2003, C-reactive protein: a critical update., J Clin Invest, 111, 1805, 10.1172/JCI200318921 Arkader, 2006, Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome., Arch Dis Child, 91, 117, 10.1136/adc.2005.077446 Navarro, 2014, Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums., Semin Arthritis Rheum, 43, 458, 10.1016/j.semarthrit.2013.08.001 Yokota, 2005, Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis., Arthritis Rheum, 52, 818, 10.1002/art.20944 Nishimoto, 2005, Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease., Blood, 106, 2627, 10.1182/blood-2004-12-4602 Ito, 2004, A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease., Gastroenterology, 126, 989, 10.1053/j.gastro.2004.01.012 Drobyski, 2011, Tocilizumab for the treatment of steroid refractory graft-versus-host disease., Biol Blood Marrow Transplant, 17, 1862, 10.1016/j.bbmt.2011.07.001 Nishimoto, 2008, Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease., Blood, 112, 3959, 10.1182/blood-2008-05-155846 Fecher, 2013, Ipilimumab and its toxicities: a multidisciplinary approach., Oncologist, 18, 733, 10.1634/theoncologist.2012-0483 Mitchell, 2005, Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial., Br J Haematol, 129, 734, 10.1111/j.1365-2141.2005.05509.x Flammiger, 2012, Critical imbalance of TNF-α and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment., Acta Haematol, 128, 69, 10.1159/000338179 Prahalad, 2001, Etanercept in the treatment of macrophage activation syndrome., J Rheumatol, 28, 2120 Gabay, 2010, IL-1 pathways in inflammation and human diseases., Nat Rev Rheumatol, 6, 232, 10.1038/nrrheum.2010.4
Thông tin
Thông tin xuất bản

Blood

Tập 124

188-195

Thông tin tác giả